explore -WSS

explore

author：Wikipedia 2025-09-28 00:52:42 - browse：9469

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Obamacare plans could cover weight loss drugs

knowledge

entertainment

WSS

In 'major milestone,' FDA approves first cell therapy for solid tumors

In 'major milestone,' FDA approves first cell therapy for solid tumors

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Obamacare plans could cover weight loss drugs

Abridge raises $150m as clinical notes automation market heats up

Abridge raises $150m as clinical notes automation market heats up

focus

explore

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Wildfire smoke exposes gaps in outdoor worker protections

Medicare Advantage enrollment grows 7.1% to 33.4 million people

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Flagship Pioneering startup Sonata Therapeutics lays off 21

Hepatitis C has a cure — but many Americans still lack access to it

MD Anderson's Padmanee Sharma responds to research credit suit

ChatGPT in medicine: STAT answers readers' burning questions

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

focus

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Researchers tackle phage therapy hurdles for wider adoption

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

New CMS data security rules will hurt Medicare, Medicaid research

As AI regulations shape up, health tech startups beg for clarity

explore

knowledge

entertainment

entertainment